HIMS reported 49% revenue growth but saw a sequential subscriber decline of 100,000, pivoting toward higher-margin branded assortments and international expansion while investing heavily in AI and supply chain infrastructure.
Hims & Hers Health, Inc. reported a net loss of $33.0 million for the third quarter of 2026, a significant decline from a net income of $15.8 million in the prior year period, despite revenue growing to $890.4 million. The company's balance sheet shows a substantial increase in goodwill and intangible assets, reflecting significant acquisition activity during the first nine months of the year.
Hims & Hers Health, Inc. increased its board size to ten and appointed Dr. Andrew Huberman as a director, effective November 4, 2026. Alongside his board role, Dr. Huberman entered into a brand marketing and advisory agreement worth $3.5 million annually, while his media company, Scicomm Media LLC, secured a $5 million annual podcast advertising contract.
Hims & Hers Health reported Q3 2026 revenue of $890.4 million, a 49% year-over-year increase driven by significant international growth and a 13% rise in subscribers to 2.8 million. The company reported a net loss of $33.0 million compared to a profit in the prior year, while tightening its full-year revenue guidance and reducing its Adjusted EBITDA outlook.
Term
Q3 2026
“In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.”
Andrew Dudum, co-founder and CEO
“In the third quarter, we continued to apply what we’ve learned to make deliberate strategic decisions to position Hims & Hers for durable, multi-year growth.”
Hims & Hers Health CLO Soleil Boughton Sells $95.6K of Stock
Soleil Boughton, CLO, sold 3,462 shares of Hims & Hers Health, Inc. at $27.60 a share, worth $95.6K in total on Oct 28, 2026. Shares held after the trade: 293,886 (-1.2%).